
Belite Bio reports US$774M in liquidity ahead of tinlarebant FDA date
The company says the FDA will not hold an advisory panel as it prepares for a Feb. 12 decision on its Stargardt disease application.

Most consolidated cash sits at WhiteFiber, while pledged ether supports borrowing and new project financing remains subject to funding conditions.

The company says the FDA will not hold an advisory panel as it prepares for a Feb. 12 decision on its Stargardt disease application.

Reliquias targets throughput of 800 tonnes a day in the second half of 2027, with its next operational update expected in January.
The provider's final review confirms the removal, while its public notice gives no dollar estimate of passive-fund selling.
The quantum-computer developer held US$497.1 million in cash and investments as it targeted a larger system for mid-2028.

About 3,000 tonnes are planned for TotalEnergies' Leuna refinery in 2027 as the partners begin testing the integrated supply chain.

Concentrate from Burswood will go to Curtin's C4P facility, with samples intended for assessment before potential refining-partner evaluation.

Only US$1.5 million is upfront; the balance depends on warrants, with first U.S. patient dosing targeted for the second quarter of 2027.

New breast and lung cancer applications aim to inform therapy choices when conventional mutation markers leave gaps.
The Texas test reactor will support equipment trials and operator training after reaching first criticality in August 2026.
Full production is targeted for 2028, with Louisiana offering a performance-based grant and the company planning 175 additional jobs.
Canada and Germany have completed competition reviews, Curaleaf says, while its offer remains outstanding until Dec. 4.
True widths remain unknown as the first Skiråsen infill hole tests resource confidence at the wholly owned Swedish gold project.
Nine-month orders rose 611 per cent, but the third-quarter adjusted EBITDA loss widened to US$37.7 million.
The copper-gold intercept lies about 55 metres down-dip of an earlier hole, supporting the company's eastern zone interpretation.
The Army-related opportunity remains subject to lease negotiations, while the reactor developer expects spending on its pilots to increase.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
Excellon would retain 19.9 per cent of the German explorer while shareholders keep their proportionate interest in its Peru-focused business.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
A US$15M partner payment arrived after quarter-end as research spending rose ahead of the Nov. 28 D-PLEX100 review goal.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
The STOXX Europe 600 advanced as AI demand optimism met higher infrastructure spending, with Nvidia results scheduled for Nov. 17.
Contracted GPU-cloud run rate includes undeployed capacity, while HIVE's year-end expansion target remains conditional on financing.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
Third-quarter capital investment rose to C$1.084 billion as higher costs outweighed gains from approved rates and peak demand.

The sale targets a second-quarter 2027 close and supports additional debt reduction and an expanded share-repurchase plan.

The power producer now expects adjusted earnings of US$12.50 to US$12.80 a share, lifting the midpoint by US$0.65.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
The board accepted its committee's recommendation on Oct. 26, citing the harvest, a stronger outlook and debt repayment.

The submission draws on studies involving more than 1,000 participants, with a first-half 2027 launch still subject to FDA approval.

Operating cash flow reached US$9.5 million as expansion spending eased, but weaker Canadian wholesale pricing reduced cannabis profit.

Free cash outflow narrowed to C$15.5 million as international sales grew, while charges on Canopy USA assets weighed on earnings.